Shares of Ocular Therapeutix Inc. (NASDAQ:OCUL) saw unusually-strong trading volume on Friday . Approximately 1,710,348 shares changed hands during mid-day trading, an increase of 8% from the previous session’s volume of 1,585,123 shares.The stock last traded at $6.63 and had previously closed at $6.30.

A number of equities analysts have recently commented on OCUL shares. Morgan Stanley reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, May 12th. Zacks Investment Research raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Friday. Cowen and Company reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Monday, June 6th. BTIG Research reissued a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, July 26th. Finally, JMP Securities started coverage on shares of Ocular Therapeutix in a research report on Thursday. They issued an “outperform” rating and a $5.84 price target on the stock. Six analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $19.07.

The stock has a 50-day moving average price of $5.18 and a 200 day moving average price of $8.20. The company’s market cap is $168.29 million.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.03. During the same quarter in the prior year, the firm posted ($0.45) earnings per share. The business earned $0.44 million during the quarter, compared to analyst estimates of $0.55 million. Ocular Therapeutix’s revenue for the quarter was down 3.9% compared to the same quarter last year. On average, equities research analysts expect that Ocular Therapeutix Inc. will post ($1.87) EPS for the current fiscal year.

In other Ocular Therapeutix news, CEO Amarpreet Sawhney acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 9th. The stock was acquired at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the transaction, the chief executive officer now owns 573,733 shares of the company’s stock, valued at $3,844,011.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.